Search for Terms or Answers
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine.
In this third excerpt from the ACR guidelines on managing reproductive health issues in rheumatic disease patients, we present recommendations regarding the use of glucocorticoids and guidance on lactation and medication use post-partum.
This podcast features a discussion of autoinflammatory and Still's disease abstracts from virtual ACR 2020. Dr. Jack Cush is joined by a panel of experts including Drs. Olga Petryna, Bella Metha and Michael Ombrello.
Saturday's session on autoinflammatory syndromes featured Dr. Dan Kastner addressing - The Adult with Undifferentiated Autoinflammatory Disease.
Gout has historically been considered a disease of the financially rich, rich in diet, and rich in alcohol.
Colchicine suppresses MSU & CA pyrophosphate crystal activation of Nod-Like Receptor Protein 3 (NLRP3) inflammasome, thereby suppressing caspase-1 activation and the subsequent release of IL-1β and IL-18. Great review by Pillinger et al https://t.co/n7MHtSviT5
Autoinflammatory & Still's Disease Panel #acr20 Dr. Jack Cush leads a panel of experts regarding Still's Disease and ACR 2020. https://t.co/4GmM56l1cb https://t.co/WbXMUtz6Up
#BestACR20Tweets RT @KDAO2011 : #FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
#BestACR20Tweets RT @KDAO2011 : FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
